GLP-1 Hair Loss: Why It Happens, How Long It Lasts, and What Actually Helps

How often does it happen in the trials?

The Wegovy, Zepbound, and Foundayo labels list hair loss among reported adverse reactions [1][3][2]. The figures below come from those tables.

The labels state that adverse reaction rates from different trials cannot be directly compared, because trial conditions and populations differ [1][2]. The Wegovy, Zepbound and Foundayo trials enrolled different groups at different doses, so the percentages do not rank one drug against another.

The diabetes labels read differently. Hair loss does not appear in the Mounjaro label's table of common adverse reactions from its type 2 diabetes trials [6], while the Ozempic label lists alopecia among postmarketing reports, for which a frequency cannot be estimated from voluntary reports [7].

Why does it happen?

The Zepbound label states that hair loss was associated with weight reduction and was more frequent in women: 7.1% of women versus 0.5% of men on tirzepatide, against 1.3% of women and 0% of men on placebo [2]. On the 7.2 mg Wegovy dose, hair loss was reported by 8.4% of women versus 0.2% of men [1].

A 2026 systematic review of 24 studies found that semaglutide and tirzepatide had the highest reported rates of hair loss and the most frequent signals among GLP-1 drugs, and that androgenetic alopecia and telogen effluvium were the two subtypes most often reported [4]. Tirzepatide, the drug with the largest weight loss in trials, was most often linked to telogen effluvium, and rapid weight loss emerged as a potential contributor, particularly for that subtype [4]. The same review found hair loss with semaglutide appeared dose-dependent, with weekly doses below 2 mg rarely implicated and the higher obesity-treatment doses more often associated with it [4].

An earlier review concluded that clinical evidence linking GLP-1 agonists to hair loss remained sparse and called for further investigation [8].

What the larger studies add

Cheng and Chang pooled 9 interventional studies, 7 randomized trials and 2 non-randomized, covering 4,114 GLP-1 users. Hair loss was more frequent than with placebo, with a risk ratio of 3.25 (95% CI 1.44 to 7.36); restricting the analysis to randomized trials in people with overweight or obesity gave 3.59 (95% CI 2.10 to 6.12), and the event rate across single-arm analyses was 3.9% [5].

A target trial emulation using electronic health records compared 12,004 GLP-1 initiators with 15,221 SGLT-2 inhibitor initiators, and separately compared 11,964 GLP-1 initiators with 11,238 DPP-4 inhibitor initiators, all adults with type 2 diabetes. GLP-1 use was associated with a higher risk of alopecia than SGLT-2 inhibitors (hazard ratio 1.37, 95% CI 1.08 to 1.73) and DPP-4 inhibitors (1.68, 1.28 to 2.20), and the association was specific to non-scarring alopecia; the authors describe the absolute risk as low, and the associations attenuated after negative control outcome calibration [9].

Pharmacovigilance reports give a mixed picture. One analysis of four adverse event databases found no positive signal for hair loss with GLP-1 drugs, although GLP-1 drugs were the class most often reported for hair loss [10]. A separate pharmacovigilance analysis found alopecia among the five most common skin reactions reported with GLP-1 drugs, with significantly more alopecia reports when the drugs were used for type 2 diabetes than for weight management (P=0.000) [11].

Is the cause settled?

The Zepbound label associates hair loss with weight reduction, and the 2026 review identifies rapid weight loss as a potential contributor, particularly to telogen effluvium [2][4]. The review concluded that further studies are needed to establish causality and the temporal relationship through large, prospective randomized trials [4].

How often did hair loss lead to stopping treatment?

In the Zepbound weight-management trials, no patient stopped treatment because of hair loss; one placebo-treated patient did [2]. Overall discontinuation for adverse reactions was 4.8% to 6.7% on Zepbound versus 3.4% on placebo, mostly for gastrointestinal reactions [2]. In the Wegovy weight trials it was 6.8% versus 3.2%, most often for nausea, vomiting and diarrhea [1].